PD-1 Inhibitor Clash in Japan: OPDIVO and KEYTRUDA Go Head-to-Head
Before 2022, OPDIVO, developed through collaborative efforts between Ono Pharmaceutical and Bristol Myers Squibb, encountered formidable market challenges within Japan's increasingly competitive oncology landscape. The therapeutic agent experienced significant market decline as KEYTRUDA vs OPDIVO competition reached critical intensity, with medical professionals demonstrating growing preference...
0 Commentaires
0 parts